Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
19 competitors in Non-Small Cell Lung Cancer
No patent data available. Pre-approval drugs may not have Orange Book listings.
Retsevmo
Retsevmo as monotherapy is indicated for the treatment of adults with: – advanced RET fusion positive non small cell lung cancer (NSCLC) not previously treated with a RET inhibitor– advanced RET fusion positive solid tumours, when treatment options not targeting RET provide limited clinical benefit, or have been exhausted (see sections 4.4 and 5.1)Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with:– advanced RET fusion positive thyroid cancer who are radioactive iodine-refractory (if radioactive iodine is appropriate)– advanced RET mutant medullary thyroid cancer (MTC)